The 5-Second Trick For Z-LEHD-fmk
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate many intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Most important trial targets had been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyosi